United Kingdom Archives

edna environment conservation genetics biotech freshwater biodiversity spygen newts

News and Trends 10 Mar 2016

How this Forensic DNA Tool can help Conserve Endangered Species in the UK

This is the story of how the Natural History Museum of Denmark and Molecular Ecology biotech Spygen (France) brought together forensic science techniques to detect traces of Great Crested Newt DNA in UK ponds. The Great Crested Newt (Triturus cristatus) is an amphibian found across Northern Europe and parts of Asia, which has been declining since […]

March 10, 2016 - 3 minutesmins - By Joachim Eeckhout

wales life sciences investment fund finance wales wao £50M chris evans arthurian

News and Trends 9 Mar 2016

Significant doubts about Welsh Government handling of Biotech VC fund

The Wales Life Sciences Fund was intended to attract Biotechs and Pharma to this part of the UK – but the governmental oversight of the establishment of this £50M fund has been criticised in a report by the Wales Audit Office… [Editor’s note: this article was initially published on March 7th, 2016. Due to some inaccuracies, we […]

March 9, 2016 - 3 minutesmins - By Joachim Eeckhout

win horizon centauri antibody avvinity cancer alphamer

News and Trends 2 Mar 2016

New Joint Venture to Shake Up Immuno-Oncology in the UK

Avvinity Therapeutics is the new child of two UK Biotechs: Horizon Discovery and Centauri. The goal? To create the ultimate immuno-oncology toolbox with€32M. Just created, Avvinity is a joint venture targeting the immuno-oncology field, which is worth around €32M – and is only expected to grow. The biotechnological approach to cancer treatments has many Pharma and Biotech companies interested, […]

March 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Mar 2016

Here’s why this leading EU Investor turned to NASH

Akarna Therapeutics (US & UK) just raised $15M (€13M) in a series B round led by Forbion Partners – one of the leading VCs from Europe. Also run by existing New York investors New Science Ventures and Third Point, the round purpose was to raise funding to develop a new drug for the liver disease Non-alcoholic steatohepatitis (NASH). I […]

March 1, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 25 Feb 2016

NGS Battle: Illumina is now suing Oxford Nanopore (and it looks suspicious)

NGS-Giant Illumina (US) is suing Oxford Nanopore (UK), the Unicorn ready to disrupt gene sequencing. What’s the story? Illumina currently has the monopoly on NGS equipment, and Illumina’s machines make a common (and bulky) fixture in labs all over the world. In the future, many hospitals will move into data-driven medicine and NGS plays an important […]

February 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

desktop genetics gene ngs illumina epigenetics

News and Trends 23 Feb 2016

UK Start-Up Gets €380k to Understand Cancer with CRISPR

Desktop Genetics, a small bioinformatics start-up out of London, has won a substantial grant to understand why some cancer cells just won’t quit. To do this, it relies on CRISPR, their expertise with genetic data, and research from Imperial College London. Desktop Genetics has already proven that it can move some money, with a €1.87 […]

February 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

clinical depression glasgow ets6103 e therapeutics

News and Trends 16 Feb 2016

Sorry Scotland, Phase II Trial for Clinical Depression Fails against 55-Year Old Generic

I mean, Clinical depression is a tough indication for Biotech to tackle – particularly when facing off a ’55-year old’ generic (amitriptyline). But e-Therapeutics in Oxford (UK) has more to offer in its pipeline, despite this phase IIb failure in Glasgow. The trial’s aims were to determine whether ETS6103 was an antidepressant capable of treating the patients for […]

February 16, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 16 Feb 2016

The Only Real European Biotech Unicorns in 2016

Unicorns are private fast-growing companies valued more than a billion euro/dollars. This club is getting bigger and bigger, 146 companies while I’m writing this article (look at the full list on the Wall Street Journal). There is a very reduced number of Biotech unicorns worldwide and even less in Europe. There are actually only 3: […]

February 16, 2016 - 3 minutesmins - By Philip Hemme

4d pharma microbiome tucana ucc ibs cork

News and Trends 15 Feb 2016

Europe’s Richest Microbiome Biotech Acquires Irish Start-up To Accelerate!

Have you ever heard of 4D pharma (UK)? Well, it’s become one of the biggest and cash-rich players in the European Microbiome scene. Perhaps the acquisition of this Irish Chronic disease spin-off will bring their name to the spotlight… 4D pharma in Leeds (England) acquired Tucana, a spin-off from the University College Cork (UCC), to complement its therapeutic platform […]

February 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

genomics england illumina 100 project partner uk

News and Trends 12 Feb 2016

World’s Largest Genome Sequencing Project partners with Global Leader in NGS

Genomics England (UK) today announce a partnership with the Next-Generation Sequencing Giant, Illumina (US), to develop a platform that can be used to improve and automate genome interpretation as part of the 100,000 Genome Project. The tools will operate within the Genomics England secure database to enable researchers and clinicians to access information and reports more readily. […]

February 12, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 8 Feb 2016

The European Union Finances the Future of CAR-T Manufacturing

CAR-T is the way forward in Cancer therapeutics, which is one of the leading causes of Mortality in the Western world. Now this European consortium has amassed €6M for a more unified approach to CAR-T under a European Union Commission program. In response to this major health issue Miltenyi Biotec (Germany) coordinates the new EU-funded project […]

February 8, 2016 - 3 minutesmins - By Dani Bancroft

medicxi venture index fund uk genmab jjdc gsk fund

News and Trends 2 Feb 2016

New €210M Life Sciences Fund is Launched in UK

Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a €210M Fund including GSK and Johnson & Johnson Innovation. Medicxi Ventures is based in London, Geneva and Jersey and has been investing in the Life Sciences field for over 20 years. It comprises all of the legacy portfolio […]

February 2, 2016 - 2 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us